Belimumab (Benlysta) for Systemic Lupus Erythematosus
June 13, 2011 (Issue: 1366)
Belimumab (Benlysta – Human Genome Sciences/GlaxoSmithKline) has been approved by the FDA for
treatment of adults with active, autoantibody-positive, systemic lupus erythematosus (SLE). It is the first biologic
agent approved for SLE and the...more
1. GS Cheema et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44:1313.
2. M Petri et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58:2453.
3. DJ Wallace et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61:1168.
4. SV Navarra et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. Lancet 2011; 377:721.
5. R Furie et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through week 76. Arthritis Rheum 2010; 62:S606. Available at www.abstracts2view.com/acr.
6. MA Petri et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with seropositive SLE: combined efficacy results from the phase 3 BLISS-52 and -76 studies. Arthritis Rheum 2010; 62:S190.
7. RF van Vollenhoven et al. Belimumab, a BLyS-specific inhibitor, reduced corticosteroid use in patients with active SLE: results from the phase 3 BLISS-52 and -76 studies. Arthritis Rheum 2010; 62:S190. Available at www.abstracts2view.com/acr.
8. WW Chatham et al. Effect of belimumab, a BLyS-specific inhibitor, on functional antibodies to pneumococcal, tetanus, and influenza vaccines. Arthritis Rheum 2010; 62:S192.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
